key: cord-0976759-dy5nljg0 authors: Zhao, Juan; Wang, Ling; Schank, Madison; Dang, Xindi; Lu, Zeyuan; Cao, Dechao; Khanal, Sushant; Nguyen, Lam N.; Nguyen, Lam N.T.; Zhang, Jinyu; Zhang, Yi; Adkins, James L.; Baird, Evan M.; Wu, Xiao Y.; Ning, Shunbin; Gazzar, Mohamed El; Moorman, Jonathan P.; Yao, Zhi Q. title: SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects date: 2021-07-27 journal: Virus Res DOI: 10.1016/j.virusres.2021.198508 sha: fa32d97147ac07ac964369326b32f71862c4d383 doc_id: 976759 cord_uid: dy5nljg0 The COVID-19 pandemic caused by SARS-CoV-2 infection poses a serious threat to public health. An explicit investigation of COVID-19 immune responses, particularly the host immunity in recovered subjects, will lay a foundation for the rational design of therapeutics and/or vaccines against future coronaviral outbreaks. Here, we examined virus-specific T cell responses and identified T cell epitopes using peptides spanning SARS-CoV-2 structural proteins. These peptides were used to stimulate peripheral blood mononuclear cells (PBMCs) derived from COVID-19-recovered subjects, followed by an analysis of IFN-γ-secreting T cells by enzyme-linked immunosorbent spot (ELISpot). We also evaluated virus-specific CD4 or CD8 T cell activation by flow cytometry assay. By screening 52 matrix pools (comprised of 315 peptides) of the spike (S) glycoprotein and 21 matrix pools (comprised of 102 peptides) spanning the nucleocapsid (N) protein, we identified 28 peptides from S protein and 5 peptides from N protein as immunodominant epitopes. The immunogenicity of these epitopes was confirmed by a second ELISpot using single peptide stimulation in memory T cells, and they were mapped by HLA restrictions. Notably, SARS-CoV-2 specific T cell responses positively correlated with B cell IgG and neutralizing antibody responses to the receptor-binding domain (RBD) of the S protein. Our results demonstrate that defined levels of SARS-CoV-2 specific T cell responses are generated in some, but not all, COVID-19-recovered subjects, fostering hope for the protection of a proportion of COVID-19-exposed individuals against reinfection. These results also suggest that these virus-specific T cell responses may induce protective immunity in unexposed individuals upon vaccination, using vaccines generated based on the immune epitopes identified in this study. However, SARS-CoV-2 S and N peptides are not potently immunogenic, and none of the single peptides could universally induce robust T cell responses, suggesting the necessity of using a multi-epitope strategy for COVID-19 vaccine design. The COVID-19 pandemic caused by SARS-CoV-2 infection poses a serious threat to global public health. As of June 15, 2021 , there have been 175,847,347 confirmed cases of COVID-19 and 3,807,276 deaths reported worldwide -with 33,140,498 confirmed cases and 594,644 deaths in the United States alone (1) . Notably, the majority of COVID-19 patients spontaneously resolve the infection, suggesting that host immunity is naturally induced in COVID-19 patients. Emerging data have revealed important insights into host immune responses, particularly the adaptive T cell response, in patients who had mild versus severe SARS-CoV-2 infection (2) (3) (4) (5) . However, it remains unclear whether T cell responses to SARS-CoV-2 play a role in the disease progression, viral clearance, or protection. Additionally, the specific viral epitopes that induce T cell responses have not yet been identified. Recent studies on SARS-CoV-2 immune responses have shown that multiple SARS-CoV-2 proteins could induce virus-specific T cell responses in SARS-CoV-2-infected individuals (6) (7) (8) . However, precise screening and identification of T cell immune epitopes using SARS-CoV-2 major structural protein peptides to stimulate memory T cells derived from COVID-19-recovered subjects for a recall response are lacking. Further analysis of these virus-specific T cell responses in COVID-19-recovered subjects may provide important information regarding the host adaptive immunity against SARS-CoV-2 infection. Also, a major obstacle to developing safe and effective therapeutics and/or vaccines against SARS-CoV-2 is the lack of knowledge regarding the specific viral epitopes that are recognized by the human immune system. Therefore, identification of these immune epitopes may foster the rational design of therapeutics and/or vaccines against future outbreaks. predicted using bioinformatics approaches (9) (10) (11) , these epitopes need to be experimentally validated using clinical samples from COVID-19-recovered patients in "real world". In this study, we characterized SARS-CoV-2 specific T cell responses and identified T cell immune epitopes using 52 S-matrix pools (comprised of 315 peptides) and 21 N-matrix pools (comprised of 102 peptides) to stimulate peripheral blood mononuclear cells (PBMCs) derived from patients who had recovered from SARS-CoV-2 infection, followed by measuring IFN-γ-secreting T cells using an enzyme-linked immunosorbent spot (ELISpot) assay. Additionally, we evaluated virus-specific CD4 or CD8 T cell activation by flow cytometry analysis. Our study provides insights into the immunogenicity of SARS-CoV-2 and, importantly, identifies the immunodominant T cell epitopes that may be responsible for the viral clearance and/or protection. These results will assist in SARS-CoV-2 vaccine design and facilitate the evaluation of vaccine effectiveness. Several of these identified epitopes are promising candidates for developing therapeutic agents against SARS-CoV-2 infection. Subjects. The study subjects were composed of two groups: 11 mild to moderate, non-hospitalized COVID-19recovered patients and 4 control subjects, including 2 healthy subjects (HS) and 2 Influenza (Flu) patients. All COVID-19 patients were diagnosed using a positive PCR nucleic acid test and had recovered at least 2 weeks after the diagnosis. Blood from HS was obtained from BioIVT (Gray, TN) and was free of HBV, HCV, and HIV infections. The healthy control samples and Flu samples were confirmed by a negative serology test. PBMCs were isolated from 30-ml of blood by Ficoll density centrifugation (GE Healthcare; Piscataway, NJ) and stored in liquid nitrogen until used. The characteristics of the COVID-19 subjects are shown in Table 1 . ELISpot assay. The SARS-CoV-2 ELISpot assay was performed using ELISpot PRO 96-well plates (Mabtech, Nacka Strand, Sweden) following the manufacturer's guidelines and published protocols (12) . Briefly, PBMCs were thawed and rested in 50-ml Corning bioreactor tubes overnight. For each subject, 100 µl of 2 x10 6 PBMCs/ml cell suspension (2 x10 5 PBMCs/well) were stimulated overnight (~16 hours) with 100 µl of SARS-CoV-2 matrix peptide pools (2 µg/ml of each peptide; JPT, Germany), SARS-CoV-2 individual peptides (2 µg/ml; JPT), mAb CD3-2 (1:500 dilution; Mabtech), CMV peptide pool control (2 µg/ml; Mabtech), or blank control (complete RPMI 1640 medium with DMSO). The numbers of SARS-CoV-2-specific IFN-γ-secreting T cells/2x10 5 PBMCs, referred to as IFN-γ spot forming cells (SFCs), were determined using an AID iSpot Reader (AID, Strasberg, Germany) and analyzed using ELISpot 7.0 Software (AID). Wells containing SFC numbers greater than mean + 3SD of the blank controls were considered positive. A dotted line is drawn in each Tables 2 and 3 . In this layout, the MP design arranges each peptide in a square matrix, and MPs comprise peptides from a single row or a single column. According to this layout, each peptide is present in two MPs. The tested MPs displaying cell stimulation pinpoints the specific peptide in the intersection on the layout. Flow cytometric analysis. Based on our Elispot results, PBMCs were cultured overnight (~16 hours) in the presence of positive MPs or single peptides at a concentration of 1 µg/mL in 96-well U-bottom plates. For CD69 activation marker staining, the cells were harvested and stained with anti-CD3-PerCP, anti-CD4-FITC, anti-CD8-FITC, or anti-CD69-PE antibodies (Biolegend, San Diego, CA) at room temperature for 30 min and then subjected to flow cytometry analysis. For intracellular cytokine staining (ICS), the assay was performed as previously described (13) . Briefly, Brefeldin A was added 4 hours before harvesting. The cells were harvested and stained with anti-CD3-PerCP, anti-CD4-FITC, or anti-CD8a-FITC antibodies as described above. Then, the cells were washed, fixed, and permeabilized with the Foxp3 Transcription Factor Staining Buffer Set (Invitrogen, Carlsbad, CA), followed by staining with anti-IFN-γ-PE antibody (Biolegend) for 45 min at room temperature. Approximately 200,000 events were collected for flow cytometry analysis. For the activationinduced marker (AIM) assay, the cells were stained with anti-CD154-FITC, anti-CD4-PE, anti-CD8-PerCP, and anti-CD137-APC antibodies. Controls for these assays included isotype control antibodies, single staining, and unstained cells, which were used for gating and compensation. Samples were analyzed by a BD AccuriC6 Plus flow cytometer and FlowJo V10 software. IgG Quantitative ELISA kit (BioVendor, Asheville, NC) and SARS-CoV-2 Surrogate Virus Neutralization Test kit (GenScript) were used to determine the concentration of S1 IgG and Neutralization antibody levels respectively in the COVID-19 convalescent plasma as described previously (14) . Statistics. The data were analyzed using Prism 7 software and are presented as mean ± SEM. The outliers were identified by the ROUT method (Q = 1.000%) and excluded from the analysis. Unpaired t-tests were used to compare means of two independent groups with equal variances, and Welch's correction was utilized if unequal variances were found. Comparisons between two groups with skewed data were analyzed using the nonparametric Mann-Whitney U test. Correlations between anti-S RBD IgG or antibody neutralization rates and SFCs were analyzed by Spearman's correlation. Details are noted in the figure legends. CoV-2 S protein is regarded as a leading target in vaccine development (15) (16) (17) . Previous studies reported the identification of putative T cell epitopes using in silico tools (18) (19) (20) (21) and evaluated T cell responses using COVID-19 patients' immune cells stimulated with SARS-CoV-2 S protein or mixed peptides (rather than discrete, individual peptide motifs) (8, 22) . Thus, we set out to identify virus-specific T cell epitopes using overlapping peptide stimulation in memory T cells from COVID-19-recovered patients, followed by ELISpot assay. To this end, we employed the JPT peptide Matrix Pools (MPs), which enables fast mapping of T-cell epitopes while utilizing minimal amounts of patient cells. The MPs consist of multiple 15mers peptides with 11overlapping amino acids in each peptide, spanning the whole sequence of the SARS-CoV-2 S-protein in such a way that T cell stimulation is optimized while the chance of missing T cell epitopes is minimized (PepMix concept). The 315 SARS-CoV-2 S-peptides were pooled according to a matrix design that generates 52 subgroups ( Table 2) . Representative ELISpot images revealed that while the control subjects HS1 and It is worth noting that there was a large variation in the response levels as well as the number of peptides recognized by memory T cells among different patients. Amongst the five tested COVID-19-recovered patients, P2 exhibited the strongest IFN-γ response, including the highest number of spot-forming cells per well (SFCs/well) and elicited responses to more peptides (38/52 MP), whereas P5 showed the poorest response (lowest SFCs/well) and elicited a response to only 5/52 MPs. Fig.1K illustrates summary data of SFCs for P1-P5, based on which we identified virus-specific epitopes by pinpointing the intersection on the mapping layout shown in Table 2 . For SARS-CoV-2 S protein, 315 peptides were pooled into 52 MPs according to the matrix design. Those MPs with positive reactions are shaded in pink, and individual peptides (highlighted in red) are pinpointed as responsible for the positive T cell response. Using this strategy, we identified 28 candidate peptides in SARS-CoV-2 S-MPs as S antigen-specific T cell epitopes. The 28 candidate peptides were then confirmed individually in a second ELISpot assay. In addition to the IFN-γ ELISpot assay, we utilized intracellular immunostaining to confirm the levels of IFN-γ + producing CD4 or CD8 T cells after stimulation with S-MPs. Fig.1L shows the flow cytometry gating strategy used to detect S-specific T cells after in vitro stimulation with the SARS-CoV-2 S-MPs, which showed a positive response in ELISpot assay. The representative plots show IFN-γ expression in CD4 and CD8 T cells from a COVID-19 patient (P2) and a control subject (Flu2). While flow cytometry appeared to be less sensitive than the ELISpot assay, CD4 and CD8 T cells from patient P2 exhibited an increase in virus-specific IFN-γ expression compared to the control subject Flu2. Fig. 1M summarizes percentages of IFN-γ + cells within CD4 or CD8 T cells. The results revealed that COVID-19-recovered patients exhibited virus-specific CD4 T cell responses, as evidenced by the increases in IFN-γ producing cells in response to stimulation with SARS-CoV-2 S-MPs. Therefore, we summarized the percentage of IFN-γ-producing CD4 and CD8 T cells based on their frequencies in the peripheral blood. Fig.1N shows that both IFN-γ + CD4 + and IFN-γ + CD8 + T cells from COVID-19-recovered patients were expanded in response to SARS-CoV-2 S-MPs compared to the controls, providing further evidence that virus-specific T cell responses are elicited in COVID-19-recovered patients. To further characterize SARS-CoV-2 specific T cell epitopes, we mapped the 28 candidate peptides by a second ELISpot assay using a single peptide stimulation. As shown in Fig. 2A showed the poorest responses (1/28 MP). The other three COVID-19 patients (P1, P7, and P10) did not show a positive response to any single S peptide stimulation (Fig. 2E, 2I, and 2L). Fig.2N summarizes the mean SFCs from the nine COVID-19-recovered patients in response to 28 S single peptides, of which we identified four virus-specific immunodominant epitopes (S42, S50, S80, and S81). Flow cytometry analysis of activation-induced marker (AIM) is a cytokine-independent assay designed to test antigen-specific T cell activation and is widely used to identify virus-or vaccine-specific T cell responses (22) (23) (24) (25) . Recent studies using the AIM assay (8, 24) revealed increased T cell activation in COVID-19 patients compared to unexposed subjects. To examine the generation of SARS-CoV-2 specific CD4 and CD8 T cells after peptide stimulation, we utilized the AIM assay to measure virus-specific T cell activation in COVID-19recovered patients. Specifically, we stimulated PBMCs from ten COVID-19-recovered patients and two control subjects (one HS and one flu) with 28 SARS-CoV-2 S single peptides as indicated. We used the CMV peptide pool and anti-CD3 mAb as positive controls and DMSO as a negative control. CD40L + and CD40L + 4-1BB + were used to determine the activation of SARS-CoV-2 specific CD4 T cells, whereas 4-1BB + and CD40L + 4-1BB + were used to determine the activation of SARS-CoV-2 CD8 T cells. Fig.2O shows the flow cytometry gating strategy for the AIM assay. Fig.2P and Fig. 2Q show the percentages of CD40L + and CD40L + 4-1BB + cells within the CD4 T cell population. The results demonstrated that 13 out of 28 (13/28) peptides and 6/28 peptides, respectively, could induce an increase in CD40L + and CD40L + 4-1BB + CD4 T cells. Fig.2R and Fig. 2S show the percentages of 4-1BB + and CD40L + 4-1BB + cells within the CD8 T cell population. These results reveal that 9/28 peptides and 13/28 peptides can increase 4-1BB + and CD40L + 4-1BB + cells within CD8 T cells. Of note, peptides S80 and S81 were identified as immunodominant epitopes in both ELISpot and AIM assays. CoV-2 S protein displays high rates of mutations (i.e., quasispecies), which can drive its resistance to neutralization antibodies and T cell responses, or the lack of protection to prophylactic vaccines (26) . In contrast, the SARS-CoV-2 N protein is relatively conserved and stable, with 90% amino acid homology among various strains, and accumulates fewer mutations over time (10) . The N proteins of many coronaviruses are highly immunogenic and expressed abundantly during viral infection (27) . An elevated N protein-induced IFNγ production has been observed in COVID-19-recovered patients (28) , indicating that SARS-CoV-2 N protein might serve as a good candidate for vaccine development (29) . To evaluate T cell responses and identify T cell Notably, P2 showed the highest T cell reactivity (320 SFCs/well) against N-MP19 stimulation. Fig.3K shows the mean ± SEM of SFCs/well for P1-P5, of which we identified five SARS-CoV-2 N-specific T cell epitopes using the same MP pinpoint principle as explained above ( Table 3) . To confirm the ELISpot assay results, we examined SARS-CoV-2 specific T cell response to N-MP19 using flow cytometry to measure the T cell early activation marker CD69. Following stimulation with N-MP 19, the PBMCs were harvested and stained for CD3, CD4, CD8, and CD69 antibodies. As shown in Fig. 3L , patient P2 exhibited a higher frequency of CD69 + cells within both CD4 and CD8 T cell populations compared to the control Flu2. The mean frequency of CD69 + cells in SARS-CoV-2 and control groups revealed that CD69 expression was elevated in both CD4 and CD8 T cell populations (Fig. 3M) and also in the overall lymphocyte population ( Fig. 3N ; adjusted by CD4 and CD8 T cell frequencies) from COVID-19-recovered patients compared to the control subjects. Moreover, these five N antigen-specific T cell epitopes were confirmed by a second ELISpot assay, using each individual peptide stimulation in the PBMCs. The representative results in Fig. 4A show that the control Flu2 subject did not respond to SARS-CoV-2 N81 and N-88 but elicited a strong response to both CMV peptide and CD3 mAb stimulation. Of note, patient P1 only responded to anti-CD3 mAb, whereas patient P2 exhibited positive responses to peptides N-81 and N-88 as well as CMV peptides and CD3 mAb stimulation (positive controls). The controls (HS1 and HS2 in Fig.4B-4C ; Flu1 and Flu2 in Fig.4D-4E ) did not respond to SARS-CoV-2 N single peptide stimulation. Fig.4F-4P shows the virus-specific T cell responses to a single N peptide in each COVID-19-recovered patient. Four out of five candidate peptides were confirmed to induce positive responses in at least one COVID-19 subject. Additionally, the AIM assay was used to identify T cell activation and virus-specific epitopes. The results demonstrated that N-81 and N-85 could induce increases in CD40L expression in CD4 T cells (Fig.4Q) , while N-81 and N-88 could induce co-expression of CD40L and 4-1BB in CD4 T cells (Fig.4R) . Similarly, only peptide N-85 increased the expression of 4-1BB in CD8 T cells (Fig.4S) , whereas, individual peptides N-81, N-85, and N-88 could induce CD40L and 4-1BB co-expression in CD8 T cells from 1 or 2 out of 10 COVID-19 patients (Fig.4T) . Taken together, these results demonstrate that peptides N-81, N-82, N-85, and N-88 are potential T cell immune epitopes that can induce T cell recall responses in some COVID-19-recovered patients. Table 4 ), which reflect the major HLA alleles in the U.S. Caucasian population. A percent (%) Rank of <0.5% was considered a strong binding (SB) predictor for MHC class I and a % Rank of <2% was considered an SB predictor for class II. The identified SARS-CoV-2 specific T cell epitopes, their peptide sequences, amino acid positions, location domains, positivity rates in tested patients, and the predicted MHC class I and II alleles are shown in Table 5 . This information will be beneficial for further investigation into SARS-CoV-2 -specific T cell responses as well as therapeutic or vaccine development. The correlation between SARS-CoV-2-specific T cell response and B cell antibody response. Because most protective B cell antibody responses are dependent upon robust CD4 helper T cell activation and cytokine production, we hypothesized that SARS-CoV-2-specific T cell responses correlate with the virus-specific antibody production in COVID-19-recovered subjects. To test this hypothesis, we measured SARS-CoV-2 humoral immune responses in COVID-19-recovered subjects and examined the relationship between T cell and B cell immune responses. Interestingly, patient P1 showed a marginally positive anti-SARS-CoV-2-RBD IgG titer with 0.229 OD at 450 nm (OD450 cutoff was set at 0.2), whereas patients P7 and P10 were IgG negative (14) . Notably, all three patients exhibited poor T cell responses to any of the single S peptide stimulations (Fig.2) . These results suggested that SARS-CoV-2 specific antibody production might be dependent upon the virus-specific T cell response in COVID-19 patients. To validate this observation, we analyzed the relationships between both S and N MP-stimulated T cell responses and anti-S RBD IgG titers as well as the rates of antibody neutralization using Spearman's Correlation analysis. As shown in Fig.4 U-V, both S-and N-specific T cell responses positively correlated with IgG titers from the same subjects. These findings are consistent with previous reports (8, 32) . Of note, we reported that SARS-CoV-2 neutralizing antibodies positively correlated with the levels of anti-S-RBD IgG antibodies (14) . We thus further analyzed the correlation between S and N MP-stimulated T cell responses and the antibody neutralization rates and identified positive correlations using this analysis (Fig4. W-X) . These results demonstrate that SARS-CoV-2 humoral immune responses positively correlate with the virus-specific T cell responses in COVID-19-recovered subjects. Our results demonstrate that virus-specific T cell recall responses are successfully generated in response to SARS-CoV-2 S and N peptide stimulation, but the levels of their overall response are not robust or universal to each viral peptide -as these responses varied amongst different patients. Notably, we have previously shown a positive correlation between the neutralizing antibody titer and anti-Spike S1 IgG concentration (14) . Also, we found that SARS-CoV-2 specific IgG and IgM antibodies were diminished quickly in some COVID-19recovered patients, i.e., within weeks to months (14) . Thus, the longevity/durability of these T cell responses should be investigated further. In essence, our results showing limited virus-specific adaptive immune responses in COVID-19-recovered patients raise concerns about reinfection in COVID19-recovered patients as well as the efficacy of protection in previously unexposed individuals following the administration of COVID-19 vaccines (33) (34) (35) . Given that protective antibodies naturally wane over time, the virus-specific T cell memory response is critically valuable to fight against SARS-CoV-2 reinfection and can be used to assess the duration of vaccine protection. Our study revealed that epitope peptides from SARS-CoV-2 S and N proteins can induce virusspecific T cell responses. However, while we found detectable T cell responses to both S and N peptides in COVID-19-recovered patients, none of the single peptides could universally induce T cell responses among all convalescent subjects, indicating that multi-epitope peptides should be used for designing prophylactic vaccines to induce a strong and broad T cell response. It should be pointed out that, without a wild-type viral challenge it is unclear whether these T cell responses -either induced by natural infection or peptide vaccines -can provide sufficient protection or induce pathological effects. In this study, we used both ELISpot and flow cytometry analysis to evaluate the peptide specific T cell response after peptide stimulation. While the ELISpot primarily focuses on IFN-γ secreting cells, the flow analysis emphasizes the markers of CD40L and 41BB as peptidespecific T cells. The ELISpot is considered to be more sensitive than flow analysis; however, flow analysis allows for the detection of peptide-specific T cells within CD4 and CD8 populations. Although factors leading to different T cell responses in our COVID-19 patients remain unclear, gender may play a role -given that in this cohort male patients (P2, P6, P8, P10, and P16) appeared to demonstrate a stronger peptide-specific T cell response. Of note, a recent study reported that female patients mount robust T cell responses compared to males in response to SARS-CoV-2 infection (36) , which is opposite of what we observed in the current study. In this context, the limited number of subjects included in our study may have contributed to this outcome. Another important aspect includes the longevity of the protective T-cell responses, which requires further investigation. Some studies reported that a durable T cell response can last for at least six months post-SARS-CoV-2 infection (37, 38) and that virus-specific T cell responses to SARS-CoV or MERS-CoV can last for 6 or 10 years (39, 40) . These studies reassure that even if the anti-SARS-CoV-2 IgG antibodies fall below detectable levels within months after infection and possibly vaccination, a robust T cell response can be maintained to combat viral reinfection. Moreover, further studies are needed to determine the molecular mechanisms that support a successful T cell response and to elucidate how pre-existing conditions, co-morbidities, immune status, and other variables can affect protective T cell responses. The datasets generated and analyzed during the course of this study are available from the corresponding author upon reasonable request. The data sharing policies of NIH and VA will be followed. 45 224 225 226 227 228 229 230 231 232 233 234 235 236 46 237 238 239 240 241 242 243 244 245 246 247 248 249 47 250 251 252 253 254 255 256 257 258 259 260 261 262 48 263 264 265 266 267 268 269 270 271 272 273 274 275 49 276 277 278 279 280 281 282 283 284 285 286 287 288 50 289 290 291 292 293 294 295 296 297 298 299 300 301 51 302 303 304 305 306 307 308 309 310 311 312 313 314 52 315 World Health Organization. Coronavirus disease (COVID-2019) situation reports Dysregulated adaptive immune response contributes to severe COVID-19 Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans Single-cell landscape of immunological responses in patients with COVID-19 T cell responses in patients with COVID-19 Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals SARS-CoV-2 specific T-cell responses and correlations with COVID-19 patient predisposition Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2 A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2 Immunogenic SARS-CoV-2 Epitopes: In Silico Study Towards Better Understanding of COVID-19 Disease-Paving the Way for Vaccine Development. Vaccines (Basel) Guidelines for the automated evaluation of Elispot assays ATM Deficiency Accelerates DNA Damage Blockade of SARS-CoV-2 spike protein-mediated cell-cell fusion using COVID-19 convalescent plasma Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study 3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2 using immunoinformatics Anti-COVID-19 multi-epitope vaccine designs employing global viral genome sequences SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 Identification of murine antigen-specific T follicular helper cells using an activation-induced marker assay Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans A Cytokine-Independent Approach To Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus Nucleocapsid Protein Recruitment to Replication-Transcription Complexes Plays a Crucial Role in Coronaviral Life Cycle Elevated nucleoprotein-induced interferon-gamma release in COVID-19 patients detected in a SARS-CoV-2 enzyme-linked immunosorbent spot assay representing the Oc. The SARS-CoV-2 N protein is a good component in a vaccine NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals COVID-19 re-infection by a phylogenetically distinct SARScoronavirus-2 strain confirmed by whole genome sequencing COVID-19 re-infection Retest positive for SARS-CoV-2 RNA of "recovered" patients with COVID-19: Persistence, sampling issues, or re-infection? Sex differences in immune responses that underlie COVID-19 disease outcomes Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection Covid-19: T cell response lasts for at least six months after infection, study shows Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study SARS to MERS: 10 years of research on highly pathogenic human coronaviruses Conceptualization, Methodology, Formal analysis, Investigation, Data Curation, Writing -Original Draft. Writing -Review & Editing. Ling Wang: Investigation, Writing -Review & Editing. Madison Schank: Investigation, Writing -Review & Editing. Xindi Dang: Investigation, Zeyuan Lu: Investigation. Dechao Cao: Investigation. Sushant Khanal: Investigation. Lam N. Nguyen: Investigation. Lam N.T. Nguyen: Investigation. Jinyu Zhang Investigation. Yi Zhang: Investigation. James L. Adkins: Resources. Evan M. Baird: Resources. Xiao Y. Wu: Project administration. Shunbin Ning: Writing -Review & Editing, Mohamed El Gazzar: Writing -Review & Editing. Jonathan P. Moorman: Writing -Review & Editing, Funding acquisition. Zhi Q. Yao: Conceptualization, Writing -Review & Editing, Supervision, Funding ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential 23 118 119 120 121 122 123 124 125 126 127 128 129 130 24 131 132 133 134 135 136 137 138 139 140 141 142 143 25 144 145 146 147 148 149 150 151 152 153 154 155 156 26 157 158 Pool# 27 28 29 30 31 32 33 34 35 36 37 38 39 40 159 160 161 162 163 164 165 166 167 168 169 170 171 41 172 173 174 175 176 177 178 179 180 181 182 183 184 Pool# 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 12 11 12 13 14 15 16 17 18 19 20 13 21 22 23 24 25 26 27 28 29